List view / Grid view
Drug discovery research is funded primarily by government and by philanthropic groups. Later development is funded mainly by pharmaceutical companies.
A research team from Instituto Gulbenkian de Ciencia (IGC, Portugal), developed a new genetic technique that allows the elimination of specific neurons of the peripheral nervous system without affecting the brain.
Karolinska development's portfolio company Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumour suppressor protein p53, announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumour suppressor protein p53 by APR-246.
The development of new treatments for pancreatic cancer is set to be transformed by a network of clinical trials, aiming to find the right trial for the right patient, after a £10 million investment from Cancer Research UK.
Sound Pharmaceuticals has been awarded up to $1.6M from Cystic Fibrosis Foundation Therapeutics (CFFT), the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
Sanofi and Lonza have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland.
Our blood stem cells generate around a thousand billion new blood cells every day. But the blood stem cells’ capacity to produce blood changes as we age. This leads to older people being more susceptible to anaemia, lowered immunity and a greater risk of developing certain kinds of blood cancer.
A research project, based out of the University of Liverpool, which will bring together a multidisciplinary team of cancer surgeons, medical oncologists and scientists in Liverpool, has been given the go ahead thanks to £200,000 worth of grant funding.
Orion and Finland are both celebrating their centenaries in 2017.
Viking Therapeutics announced positive initial results from a proof-of-concept study of VK2809 in an in vivo model of glycogen storage disease Ia (GSD Ia).
Polyphor has received a CHF 2.3 million award from the Wellcome Trust to advance the development of broad-spectrum, Gram-negative pre-clinical product candidates.
The research group will explore novel approaches to vaccine development, focusing on the Zika virus.
A team of scientists from Austria, Australia, Denmark, England and the Czech Republic, led by Christian Gruber from the MedUni Vienna's Institute of Pharmacology, managed to isolate a neuropeptide from ants that is very similar to the human love hormone oxytocin, and the closely related hormone vasopressin.
Pharma companies involved include Allergan, AstraZeneca, Biogen, GlaxoSmithKline, Novartis, and Pfizer.
Neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease are a global health, economic and social emergency.
Harvard University researchers have developed a multiregional brain-on-a-chip that models the connectivity between three distinct regions of the brain.
